Apratastat

Drug Profile

Apratastat

Alternative Names: TMI-005

Latest Information Update: 10 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Wyeth
  • Class Anti-inflammatories; Antirheumatics; Morpholines; Small molecules
  • Mechanism of Action Matrix metalloproteinase inhibitors; Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 11 Jul 2005 Data presented at the Annual European Congress of Rheumatology (EULAR-2005) have been added to the adverse events and Rheumatoid Arthritis pharmacodynamics sectionS ,,
  • 16 Nov 2004 Phase-II clinical trials in Rheumatoid arthritis in Canada (PO)
  • 16 Nov 2004 Phase-II clinical trials in Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top